Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Medi-Radiopharma is developing a novel technetium-99m (99mTc) labeled radiopharmaceutical kit specifically designed for the diagnostic detection of myocardial diseases. This project, supported by the Hungarian government grant GINOP-2.1.1-15, aims to expand the company's portfolio of cardiac imaging agents beyond their existing commercial products like Medi-Mibi (99mTc-MIBI). The diagnostic kit is intended for use in nuclear medicine to visualize myocardial tissue and identify pathological changes. As of the latest reports, the project is in the preclinical development phase, focusing on the formulation and manufacturing processes required for a sterile, closed-system diagnostic product.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 99mTc-labeled myocardial diagnostic kit (Medi-Radiopharma).